METROPOLISMetropolis Healthcare Ltd.
Metropolis Healthcare Q2 FY27 Results: Consolidated Net Profit ₹75.48 Crore on Total Income of ₹505 Crore
- Earnings
- pathology services
Reviewed byKeshav SehgalBlacklitt Research
Metropolis Healthcare (NSE: METROPOLIS) reported consolidated total income of ₹505.31 crore and net profit of ₹75.48 crore for the quarter ended 30 Sep 2026, it said in a filing on 03 Nov 2026. Standalone total income was ₹425.92 crore and standalone net profit ₹68.75 crore for the same quarter.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹505.31 crore, up 17.5% YoY and 11.0% QoQ
- Net profit and EPS: ₹75.48 crore, up 42.7% YoY; basic EPS ₹3.64
- Other income: ₹8.49 crore, against ₹0.89 crore a year earlier
- Finance costs: ₹6.99 crore, up 22.9% YoY
Standalone
The company on its own, without its subsidiaries
- Total income: ₹425.92 crore, up 19.0% YoY and 12.8% QoQ
- Net profit and EPS: ₹68.75 crore, up 47.4% YoY; basic EPS ₹3.32
- Other income: ₹8.99 crore, against ₹2.52 crore a year earlier
- Interim dividend: ₹1 per share on face value ₹2, record date 09 Nov 2026
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 505.31 | 430.08 | +17.5% | 455.32 | +11.0% | |
| Revenue from operations | 496.82 | 429.19 | +15.8% | 450.21 | +10.4% |
| Other income | 8.49 | 0.89 | +853.1% | 5.10 | +66.4% |
| 75.48 | 52.89 | +42.7% | 56.88 | +32.7% | |
| Profit before tax | 102.48 | 71.03 | +44.3% | 77.71 | +31.9% |
| Finance costs | 6.99 | 5.68 | +22.9% | 6.18 | +13.0% |
| Depreciation | 33.05 | 32.41 | +2.0% | 32.40 | +2.0% |
| Tax expense | 27.00 | 18.14 | +48.9% | 20.83 | +29.6% |
| Net profit margin | 14.94% | 12.30% | +2.64 pp | 12.49% | +2.44 pp |
| EPS, basic (₹) | 3.64 | 2.54 | +43.3% | 2.73 | +33.3% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit grew faster than total income. Consolidated net profit rose 42.7% to ₹75.48 crore, while total income rose 17.5%, and profit before tax rose 44.3% to ₹102.48 crore. Tax expense rose 48.9% to ₹27.00 crore, which is 26.3% of profit before tax.
Other income of ₹8.49 crore is 8.3% of profit before tax, against ₹0.89 crore a year earlier. Finance costs of ₹6.99 crore are 1.4% of total income, against ₹5.68 crore a year earlier.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 425.92 | 357.98 | +19.0% | 377.47 | +12.8% | |
| Revenue from operations | 416.93 | 355.46 | +17.3% | 372.28 | +12.0% |
| Other income | 8.99 | 2.52 | +256.7% | 5.19 | +73.3% |
| 68.75 | 46.63 | +47.4% | 50.58 | +35.9% | |
| Profit before tax | 93.85 | 61.93 | +51.6% | 66.38 | +41.4% |
| Finance costs | 5.55 | 3.97 | +39.8% | 4.77 | +16.2% |
| Depreciation | 28.32 | 27.79 | +1.9% | 27.81 | +1.8% |
| Tax expense | 25.10 | 15.44 | +62.6% | 15.72 | +59.7% |
| Net profit margin | 16.14% | 13.03% | +3.11 pp | 13.40% | +2.74 pp |
| EPS, basic (₹) | 3.32 | 2.25 | +47.6% | 2.44 | +36.1% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone net profit rose 47.4% to ₹68.75 crore, faster than the 19.0% rise in total income and the 51.6% rise in profit before tax to ₹93.85 crore. Tax expense of ₹25.10 crore is 26.7% of profit before tax, against ₹15.44 crore a year earlier.
Standalone other income of ₹8.99 crore is 9.6% of profit before tax. Depreciation of ₹28.32 crore was little changed from ₹27.79 crore a year earlier. The standalone results show a loss after tax of ₹0.71 million from discontinued operations in the quarter ended 30 Jun 2026 and none in the quarter ended 30 Sep 2026.
Consolidated net profit of ₹75.48 crore is ₹6.73 crore higher than standalone net profit of ₹68.75 crore. The filing states that the EQAS Division was transferred to subsidiary Metropolis Quality Solutions Private Limited as a going concern on a slump sale basis, under a Business Transfer Agreement effective 27 Aug 2026.
The company says it has one reportable segment, pathology service. The filing states that an exceptional item of ₹7.96 crore standalone and ₹8.99 crore consolidated arose in the year ended 31 Mar 2026 for gratuity and leave encashment under the Labour Codes; no exceptional item appears in the quarter ended 30 Sep 2026.
Inference
The board declared an interim dividend of ₹1 per equity share of face value ₹2 for FY 2026-27, to be paid within 30 days of declaration, with a record date of 09 Nov 2026. The filing gives the share count of 20,75,28,996 but not the total payout for the quarter.
The filing does not state the reason for the rise in revenue and profit, the reason other income rose sharply from the year-earlier quarter, or what effect the EQAS Division transfer will have on future revenue and profit.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
